| Fiscal period | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Period End Date | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | 12/31/2011 |
|---|
| Revenues : Product sales | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Contract revenue | 42.66 | 41.82 | 93.77 | -- | -- | -- | -- | -- | -- | -- |
| Revenues : Royalties | 33.80 | 46.98 | 128.56 | 88.69 | 59.42 | 38.19 | 29.99 | 23.58 | 14.07 | 9.21 |
| Revenues : Sale of royalty rights, net | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenues:Material sales | -- | -- | -- | 22.07 | 22.50 | 27.66 | 28.49 | 19.07 | 9.43 | 12.12 |
| Captisol | 109.96 | 31.49 | 29.12 | -- | -- | -- | -- | -- | -- | -- |
| Revenues : Collaborative research and development and other revenues | -- | -- | -- | 30.35 | 27.05 | 6.06 | 6.06 | 6.32 | 7.88 | 8.70 |
| Total Revenues | 186.42 | 120.28 | 251.45 | 141.10 | 108.97 | 71.91 | 64.54 | 48.97 | 31.39 | 30.04 |
| Cost of Products Sold | -- | -- | -- | 5.37 | 5.57 | 5.81 | 9.14 | 5.73 | 3.60 | 4.91 |
| Contract manufacturing | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cost of Captisol | 30.42 | 11.35 | 6.34 | -- | -- | -- | -- | -- | -- | -- |
| Amortization of intangibles | 23.44 | 16.86 | 15.79 | 12.12 | 10.64 | 2.38 | 2.38 | -- | -- | -- |
| Research and development | 59.39 | 55.91 | 27.86 | 26.89 | 21.22 | 11.01 | 9.75 | 9.27 | 10.79 | 10.29 |
| Write-off of acquired in-process research and development | -- | -- | -- | -- | -- | -- | -- | 0.48 | 0.00 | 2.28 |
| General and Administrative | 64.44 | 41.88 | 37.73 | 28.65 | 27.65 | 25.40 | 22.57 | 17.98 | 15.78 | 14.58 |
| Lease termination costs | -- | -- | -- | -- | -- | -- | (1.08) | (0.56) | (1.02) | (0.55) |
| Write-off of acquired technology | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Co-promotion | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Accretion of deferred gain on sale leaseback | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.70 |
| Gain from sale of Promacta license | -- | 812.80 | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain from sale of Vernalis R&D | 17.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Expenses | 177.69 | 126.00 | 87.73 | 73.03 | 65.09 | 44.59 | 44.91 | 34.03 | 31.20 | 32.62 |
| Operating income | 25.85 | 807.08 | 163.73 | 68.08 | 43.89 | 27.33 | 19.63 | 14.94 | 0.19 | (0.88) |
| Interest expense | 27.42 | 35.75 | 48.28 | 13.46 | 12.84 | 11.80 | 4.86 | 2.08 | 2.92 | 2.30 |
| Gain on deconsolidation of Viking Therapeutics, Inc | -- | -- | -- | -- | -- | 28.19 | 0.00 | 0.00 | -- | -- |
| Gain (loss) from short-term investments | (16.93) | 1.05 | 50.38 | -- | -- | -- | -- | -- | -- | -- |
| Equity in net losses from Viking Therapeutics | -- | -- | -- | (2.05) | (23.13) | (5.14) | 0.00 | -- | -- | -- |
| Interest income | 8.08 | 28.43 | 14.00 | 2.06 | 0.66 | -- | -- | -- | -- | -- |
| Other, net | (0.11) | (4.17) | (6.50) | 2.60 | (0.62) | 1.77 | 1.67 | (0.06) | 0.52 | 0.63 |
| Debt conversion expense | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Decrease in liability for contingent value rights | -- | -- | -- | -- | -- | (5.01) | (5.14) | (3.60) | (1.65) | (1.01) |
| Pro-rata non-cash net losses of Viking Therapeutics, Inc | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- |
| Total other (expense) income, net | (36.38) | (10.44) | 9.60 | (10.85) | (35.93) | 8.00 | (8.32) | (5.74) | -- | -- |
| Income (loss) from continuing operations before income taxes | (10.54) | 796.64 | 173.33 | 57.23 | 7.96 | 35.33 | 11.30 | 9.21 | (3.87) | (3.56) |
| Deferred benefit: Federal | (15.67) | 74.63 | 29.93 | 44.08 | 10.53 | (167.41) | 0.41 | 0.40 | (0.91) | (10.80) |
| Deferred benefit : State | (3.38) | 0.20 | (0.19) | 0.23 | (0.24) | (24.72) | (0.03) | (0.06) | (0.30) | (3.13) |
| Income tax benefit from continuing operations | (7.55) | 167.34 | 30.01 | 44.68 | 10.33 | (192.12) | 0.41 | 0.37 | (1.19) | (13.27) |
| Current Benefit : Federal | 10.89 | 89.47 | -- | -- | 0.02 | 0.01 | 0.02 | 0.00 | 0.00 | 0.52 |
| Current Benefit : State | 0.59 | 3.10 | 0.42 | 0.11 | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 | 0.14 |
| Current Benefit : Foreign | 0.02 | (0.07) | (0.16) | 0.26 | -- | -- | -- | -- | -- | -- |
| Income from continuing operations including noncontrolling interests | -- | -- | -- | -- | -- | -- | -- | 8.83 | -- | -- |
| Loss from continuing operations | -- | -- | -- | -- | (2.37) | 227.44 | 10.89 | 8.83 | (2.67) | 9.71 |
| Income from Discontinued Operations | -- | -- | -- | -- | 0.73 | 0.00 | 0.00 | 2.59 | 2.15 | 0.00 |
| Discontinued operations : Income (loss) from discontinued operations before income taxes | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Discontinued operations : Gain on sale of AVINZA Product Line before income taxes | -- | -- | -- | -- | -- | -- | -- | -- | 3.66 | -- |
| Discontinued operations : Gain (loss) on sale of Oncology Product Line before income taxes | -- | -- | -- | -- | 1.14 | 0.00 | 0.00 | -- | -- | 0.00 |
| Discontinued operations : Income tax benefit (expense) on discontinued operations | -- | -- | -- | -- | (0.41) | -- | -- | -- | (1.51) | -- |
| Loss before cumulative effect of a change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of changing method of accounting for variable interest entity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income | (2.99) | 629.30 | 143.32 | 12.56 | -- | -- | 10.89 | 11.42 | (0.53) | -- |
| Net loss attributable to noncontrolling interests | -- | -- | -- | -- | -- | (2.38) | (1.13) | -- | -- | -- |
| Net Income (loss) Available to Common Shareholders | (2.99) | 629.30 | 143.32 | 12.56 | (1.64) | 229.82 | 12.02 | 11.42 | (0.53) | 9.72 |
| EPS (Basic) : Loss from continuing operations | -- | -- | -- | -- | (0.11) | 11.61 | 0.59 | 0.43 | (0.14) | 0.49 |
| EPS (Basic) : Income (loss) from discontinued operations | -- | -- | -- | -- | 0.04 | -- | 0.00 | 0.13 | 0.11 | 0.00 |
| EPS (Basic) : Cumulative effect of changing method of accounting for variable interest entity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Basic) | (0.18) | 33.13 | 6.77 | 0.60 | (0.08) | 11.61 | 0.59 | 0.56 | (0.03) | 0.49 |
| EPS (Diluted) : Loss from continuing operations | -- | -- | -- | -- | (0.11) | 10.83 | 0.56 | 0.43 | (0.14) | 0.49 |
| EPS (Diluted) : Income (loss) from discontinued operations | -- | -- | -- | -- | 0.04 | -- | 0.00 | 0.12 | 0.11 | 0.00 |
| EPS (Diluted) : Cumulative effect of changing method of accounting for variable interest entity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Diluted) | (0.18) | 31.85 | 5.96 | 0.53 | (0.08) | 10.83 | 0.56 | 0.55 | (0.03) | 0.49 |
| Weighted Average Shares Outstanding (Basic) | 16.19 | 19.00 | 21.16 | 21.03 | 20.83 | 19.79 | 20.42 | 20.31 | 19.85 | 19.66 |
| Weighted Average Shares Outstanding (Diluted) | 16.19 | 19.76 | 24.07 | 23.48 | 20.83 | 21.23 | 21.43 | 20.75 | 19.85 | 19.71 |